🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

226 results for “Pfizer” Clear

  1. LPA1 antagonist, Placebo for BMS-986278, LPA1 antagonist

    Bristol-Myers Squibb / Pfizer EEIG

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  2. Lonsurf 15 mg/6.14 mg film-coated tablets, Relatlimab + Nivolumab Fixed Dose Combination (FDC), Lonsurf 20 mg/8.19 mg film-coated tablets, Stivarga 40 mg film-coated tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  3. METHOTREXATE, Dazukibart, AZATHIOPRINE, HYDROCORTISONE, DEXAMETHASONE, METHYLPREDNISOLONE, CHLOROQUINE PHOSPHATE, MYCOPHENOLATE MOFETIL, BETAMETHASONE, METHYLPREDNISOLONE, PREDNISOLONE, TRIAMCINOLONE ACETONIDE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, DEFLAZACORT, BETAMETHASONE, PREDNISONE, BUDESONIDE, METHOTREXATE

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Idiopathic Inflammatory Myopathy (including dermatomyositis or polymyositis)

    phase 3 small molecule active

    1 trial

  4. MRTX1719, CARBOPLATIN, CISPLATIN, PEMETREXED, MRTX1719 Matching Placebo, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, PACLITAXEL

    Bristol-Myers Squibb / Pfizer EEIG

    metastatic non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  5. NIRMATRELVIR, NIRMATRELVIR, Ritonavir, nirmatrelvir / ritonavir

    Pfizer Ireland Pharmaceuticals Unlimited Company

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  6. Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, Imnovid 2 mg hard capsules, Privigen 100 mg/ml solution for infusion, ELRANATAMAB, Imnovid 3 mg hard capsules

    Pfizer Ireland Pharmaceuticals Unlimited Company

    MULTIPLE MYELOMA

    phase 3 small molecule active

    1 trial

  7. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Participants with completely resected Stage III or Stage IV melanoma

    phase 3 small molecule active

    1 trial

  8. Nivolumab Subcutaneous, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  9. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Sodium chloride 0.9%, solution for infusion, 5% Dextrose, solution for infusion

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors

    phase 3 small molecule active

    1 trial

  10. OPDIVO 10 mg/mL concentrate for solution for infusion., LENVATINIB, YERVOY 5 mg/ml concentrate for solution for infusion, Sorafenib 200mg Film-Coated Tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  11. OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab

    Bristol-Myers Squibb / Pfizer EEIG

    Previously Untreated Metastatic or Unresectable Melanoma

    phase 3 small molecule active

    1 trial

  12. ORENCIA 250 mg powder for concentrate for solution for infusion, METHOTREXATE/PFIZER, ORENCIA 250 mg powder for concentrate for solution for infusion, ORENCIA 250 mg powder for concentrate for solution for infusion, DRL_AB

    Reddy Holding GmbH

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  13. OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, BNT327 20 mg ml, CAPECITABINE, BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BNT327 50 mg ml, CAPECITABINE

    Bristol-Myers Squibb / Pfizer EEIG

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  14. Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl, Ozanimod HCl, FINGOLIMOD, Ozanimod HCl 0.23 mg , Ozanimod HCl 1 mg , Ozanimod HCl 0.0575 mg , Ozanimod HCl 0.25 mg, Fingolimod 0.25 mg capsule, Fingolimod 0.5 mg capsule

    Bristol-Myers Squibb / Pfizer EEIG

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  15. Ozanimod, Ozanimod, Ozanimod

    Bristol-Myers Squibb / Pfizer EEIG

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  16. PACLITAXEL, PF-08634404, SODIUM CHLORIDE, PACLITAXEL ALBUMIN-BOUND, PEMBROLIZUMAB, CARBOPLATIN, PEMETREXED

    Pfizer Ireland Pharmaceuticals Unlimited Company

    LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    phase 3 small molecule active

    1 trial

  17. PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. PEMETREXED, PALONOSETRON, Adagrasib, PEMBROLIZUMAB, CARBOPLATIN, tablets, CISPLATIN

    Bristol-Myers Squibb / Pfizer EEIG

    Locally Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg

    Pfizer Ireland Pharmaceuticals Unlimited Company

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  20. PLACEBO FOR PF-06651600-15 CAPSULE, 100 MG, Ritlecitinib Tosilate, PLACEBO FOR PF-06651600-15 CAPSULE, 50 MG, Ritlecitinib tosilate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Alopecia areata

    phase 3 small molecule active

    1 trial

  21. Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL

    Bristol-Myers Squibb / Pfizer EEIG

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  22. Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  23. Placebo for PF-06651600-15, 50 mg, DEXAMETHASONE, Ritlecitinib tosilate, Placebo for PF-06651600-15, 100 mg, Ritlecitinib Tosilate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    nonsegmental vitiligo

    phase 3 small molecule active

    1 trial

  24. Placebo to Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6), Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6)

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Group B streptococcus (GBS) disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources